There is limited information on best practices regarding urine drug testing (UDT) during long-term opioid therapy for cancer pain.1 Practices involve random UDT1 or UDT based on risk for nonmedical opioid use.2 The main objective of this study was to report the frequency of abnormal UDT findings among patients who underwent random vs targeted testing.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Arthur J, Lu Z, Nguyen K, et al. Random vs Targeted Urine Drug Testing Among Patients Undergoing Long-term Opioid Treatment for Cancer Pain. JAMA Oncol. Published online February 06, 2020. doi:10.1001/jamaoncol.2019.6756
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: